To determine whether the components of the uPA system could be used as biomarkers for severe pulmonary involvement in SSc, we investigated the association between the serum uPA, PAI-1, and suPAR levels and the presence of lung interstitiopathy, restrictive lung disease, and reduced DLCO. This evidence concerns the gene PLAU and systemic sclerosis.